2023年9月7-9日，全球肝癌领域学术盛典——第十七届国际肝癌协会（ILCA）年会（ILCA 2023）在荷兰首府阿姆斯特丹隆重召开。来自世界各地的肝癌专家共同集结在一起，共同探讨肝癌基础与临床的热点话题及最新进展！大会共收录了来自全球近千位学者的最新研究成果。本文特将本届ILCA大会上肝癌治疗领域的重磅临床研究进行汇总，供广大同道学习交流。

 

 

最新临床研究进展，最热临床研究方向

ILCA 2023

 

4项大会口头报告

 

SIRT联合纳武利尤单抗治疗期间，肝细胞癌患者的外周血T细胞受体库的多样化与其临床获益相关

 

O-13 Diversification of peripheral blood T cell receptor repertoire during treatment with SIRT plus Nivolumab is associated with clinical benefit in patients with hepatocellular carcinoma.

 

报告人：Enrique Conde-Gallastegi

 

T+A治疗超“up-to-seven”标准不适合TACE治疗的中期肝细胞癌患者的有效性和安全性：REPLACEMENT 研究

 

O-14 Efficacy and safety analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.

 

报告人：Masatoshi Kudo

 

针对T+A难治的晚期肝细胞癌或肝胆管癌患者基于肿瘤生物学的靶向治疗

 

O-15 Targeted therapy adapted to tumor biology in patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma refractory to atezolizumab/bevacizumab.

 

报告人：Wendy Limousin

 

新辅助免疫疗法在可切除肝细胞癌中的应答预测因素：PRIME-HCC研究初步临床和转化分析

 

O-16 Predictors of response to neoadjuvant immunotherapy in resectable hepatocellular carcinoma: preliminary clinical and translational analyses from the PRIME-HCC study.

 

报告人：Antonio D'Alessio

 

9项获奖优秀壁报

 

PROASH模型证实真实世界中T+A治疗较索拉非尼使肝癌患者生存获益

 

P-11 Application of PROASH model confirms survival benefit in patients treated with atezolizumab and bevacizumab compared to sorafenib in real-world setting

 

报告人：Tim Meyer

 

转录组学分析揭示SIRT联合纳武利尤单抗治疗肝细胞癌患者临床获益相关的非免疫性肿瘤微环境特征

 

P-12 Transcriptomic analysis reveals non-immune tumor microenvironment features associated with clinical benefit in patients with hepatocellular carcinoma treated with SIRT plus nivolumab

 

报告人：Enrique Conde-Gallastegi

 

肝硬化患者肝癌筛查的经济负担和心理负担

 

P-13 Financial and psychological burden of HCC surveillance in patients with cirrhosis

 

报告人：Manasa Narasimman

 

T+A治疗不适合TACE的中晚期HCC患者成功实现无瘤和无药物控制状态：一项多中心概念验证研究

 

P-14 Achievement of cancer and drug-free status by atezolizumab plus bevacizumab followed by curative conversion in patients with TACEunsuitable, intermediate-stage HCC: a multicenter proof-of-concept Study

 

报告人：Masatoshi Kudo

 

肝活检VETC（包裹肿瘤簇的血管）评估可预测晚期HCC抗血管生成治疗的临床获益

 

P-15 VETC (vessel that encapsulate tumor cluster) evaluated in liver biopsy predicts anti-angiogenic benefit in advanced HCC

 

报告人：Camilla De Carlo

 

肝细胞癌基因组和蛋白质组分析揭示与临床结果和治疗靶点相关的肿瘤亚型

 

P-16 Integrative analysis of genomic and proteomic data of hepatocellular carcinoma reveals consensus subtypes associated with clinical outcomes and therapeutic targets

 

报告人：Ju-Seog Lee

 

肝功能失代偿下的肝癌风险与体重指数的关系

 

P-17 Association with body mass index and risk of hepatocellular carcinoma according to liver disorder status

 

报告人：Baek Gyu Jun

 

DEB-TACE与常规TACE治疗肝细胞癌伴门静脉癌栓的随机临床试验

 

P-19 Drug-eluting beads vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial

 

报告人：Tan-Yang Zhou

 

针对肝超声显像不理想的肝癌患者采用非增强造影MRI监测的前瞻性研究

 

P-20 Prospective study of surveillance non-contrast abbreviated mri for hepatocellular cancer in patients with suboptimal hepatic visualisation on ultrasound

 

报告人：Mathew Vithayathil

 

 

声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。